Justin Ferdinandus

13PUBLICATIONS

52CO-AUTHORS

Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityHaematology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 30, 2026

Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma.

|Feb 09, 2026

MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.

Jan-Michel Heger, Julia Mattlener, Helen Kaul

|Oct 11, 2025

Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma.

Marie Lommen, Jasmin J Weindler, Janina Jablonski

|Aug 11, 2025

Working towards harmonization of clinical trial reporting in Hodgkin lymphoma.

Carsten Kobe, Philippe Armand, Sven Borchmann

|Jul 17, 2025

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Justin Ferdinandus, Helen Kaul, Alexander Fosså

|Mar 30, 2025

Correction: Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

P J Bröckelmann, H Müller, M Fuchs

Pageof 3

Frequent Collaborators

Carsten Kobe

Bastian von Tresckow

Paul J Bröckelmann

Dennis A Eichenauer

Hishan Tharmaseelan

S Borchmann

W Klapper

Gundolf Schneider

Julia Mattlener

Jan-Michel Heger

Frequent Collaborators

Carsten Kobe

Bastian von Tresckow

Paul J Bröckelmann

Dennis A Eichenauer